RhumbLine Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

RhumbLine Advisers’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45M	Buy	123,398 +21,613	+21%	+$1.2M	0.01%	1258
2026 Q1	$5.92M	Buy	101,785 +11,642	+13%	+$536K	0.01%	1314
2025 Q4	$4.04M	Sell	90,143 -16,648	-16%	-$699K	﹤0.01%	1510
2025 Q3	$4.29M	Sell	106,791 -2,909	-3%	-$102K	﹤0.01%	1512
2025 Q2	$3.43M	Buy	109,700 +109,671	+378,176%	+$3.58M	﹤0.01%	1607
2025 Q1	$972	Hold	29	–	–	﹤0.01%	4033
2024 Q4	$1.14K	Hold	29	–	–	﹤0.01%	4072
2024 Q3	$1.14K	Hold	29	–	–	﹤0.01%	4090
2024 Q2	$1.13K	Hold	29	–	–	﹤0.01%	4231
2024 Q1	$1.25K	Buy	+29	New	+$1.33K	﹤0.01%	4128

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RhumbLine Advisers's XENE Position: Q2 2026 in Review

RhumbLine Advisers increased its Xenon Pharmaceuticals (XENE) stake by 21% in Q2 2026, buying an estimated $1.2M and bringing the position to 123,398 shares worth $7.45M. The position accounts for 0.01% of the portfolio, ranked #1258.

RhumbLine Advisers first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

RhumbLine Advisers held 123,398 shares of Xenon Pharmaceuticals worth $7.45M as of Q2 2026.
RhumbLine Advisers bought 21,613 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
Xenon Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1258 holding.
RhumbLine Advisers first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.